These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. No Helicobacter pylori, no Helicobacter pylori-associated peptic ulcer disease. Tytgat GN Aliment Pharmacol Ther; 1995; 9 Suppl 1():39-42. PubMed ID: 7495941 [TBL] [Abstract][Full Text] [Related]
10. Maintenance therapy with H2-receptor antagonist until assessment of Helicobacter pylori eradication can reduce recurrence of peptic ulcer after successful eradication of the organism: prospective randomized controlled trial. Murakami K; Sato R; Okimoto T; Watanabe K; Nasu M; Kodama M; Fujioka T J Gastroenterol Hepatol; 2006 Jun; 21(6):1048-53. PubMed ID: 16724993 [TBL] [Abstract][Full Text] [Related]
11. Causal role of Helicobacter pylori in peptic ulcer relapse. Asaka M; Ohtaki T; Kato M; Kudo M; Kimura T; Meguro T; Horita S; Inoue K J Gastroenterol; 1994 Jul; 29 Suppl 7():134-8. PubMed ID: 7921146 [TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up after eradication of Helicobacter pylori with omeprazole, clarithromycin, and tinidazole (OCT regimen) in a Japanese population. Ando T; Minami M; Mizuno T; Watanabe O; Ishiguro K; Ina K; Kusugami K; Nobata K; Nishiwaki T; Tsuzuki T; Shimada M; El-Omar E; Goto H Helicobacter; 2005 Oct; 10(5):379-84. PubMed ID: 16181347 [TBL] [Abstract][Full Text] [Related]
14. Recurrence of Helicobacter pylori infection and the long-term outcome of peptic ulcer after successful eradication in Japan. Seo M; Okada M; Shirotani T; Nishimura H; Maeda K; Aoyagi K; Sakisaka S J Clin Gastroenterol; 2002 Feb; 34(2):129-34. PubMed ID: 11782605 [TBL] [Abstract][Full Text] [Related]
16. Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection. Labenz J; Börsch G Am J Gastroenterol; 1994 Oct; 89(10):1785-8. PubMed ID: 7942667 [TBL] [Abstract][Full Text] [Related]
18. [Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors]. Hong EJ; Park DI; Oh SJ; Song MJ; Choi WH; Hong CH; Park JH; Kim HJ; Cho YK; Shon CI; Jeon WK; Kim BI Korean J Gastroenterol; 2008 Aug; 52(2):80-5. PubMed ID: 19077498 [TBL] [Abstract][Full Text] [Related]
19. Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer. Hu FL; Jia JC; Li YL; Yang GB J Int Med Res; 2003; 31(6):469-74. PubMed ID: 14708410 [TBL] [Abstract][Full Text] [Related]
20. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. Schwartz H; Krause R; Sahba B; Haber M; Weissfeld A; Rose P; Siepman N; Freston J Am J Gastroenterol; 1998 Apr; 93(4):584-90. PubMed ID: 9576452 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]